3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
8
Carcinoma, Merkel Cell
6
Neoplasm Metastasis
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Penile Squamous Cell Carcinoma (PSCC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
pembrolizumab
4
atezolizumab
3
Cetuximab
3
olaparib
2
Trastuzumab
2
Docetaxel
2
zimberelimab
1
tocilizumab
1
spartalizumab
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
encorafenib
1
cemiplimab
1
binimetinib
1
anlotinib
1
amivantamab
1
alectinib
1
adagrasib
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
avelumab
×
90 days
×
Clear all
No trials found.